KEGG   ORTHOLOGY: K06625
Entry
K06625                      KO                                     

Name
CDKN1A, P21, CIP1
Definition
cyclin-dependent kinase inhibitor 1A
Pathway
map01522  Endocrine resistance
map01524  Platinum drug resistance
map04012  ErbB signaling pathway
map04066  HIF-1 signaling pathway
map04068  FoxO signaling pathway
map04110  Cell cycle
map04115  p53 signaling pathway
map04151  PI3K-Akt signaling pathway
map04218  Cellular senescence
map04630  JAK-STAT signaling pathway
map04921  Oxytocin signaling pathway
map04928  Parathyroid hormone synthesis, secretion and action
map04934  Cushing syndrome
map05160  Hepatitis C
map05161  Hepatitis B
map05163  Human cytomegalovirus infection
map05165  Human papillomavirus infection
map05166  Human T-cell leukemia virus 1 infection
map05167  Kaposi sarcoma-associated herpesvirus infection
map05169  Epstein-Barr virus infection
map05200  Pathways in cancer
map05202  Transcriptional misregulation in cancer
map05203  Viral carcinogenesis
map05205  Proteoglycans in cancer
map05206  MicroRNAs in cancer
map05210  Colorectal cancer
map05211  Renal cell carcinoma
map05212  Pancreatic cancer
map05213  Endometrial cancer
map05214  Glioma
map05215  Prostate cancer
map05216  Thyroid cancer
map05217  Basal cell carcinoma
map05218  Melanoma
map05219  Bladder cancer
map05220  Chronic myeloid leukemia
map05222  Small cell lung cancer
map05223  Non-small cell lung cancer
map05224  Breast cancer
map05225  Hepatocellular carcinoma
map05226  Gastric cancer
Disease
H00030  Cervical cancer
Brite
KEGG Orthology (KO) [BR:ko00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04012 ErbB signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04630 JAK-STAT signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04066 HIF-1 signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04068 FoxO signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04151 PI3K-Akt signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
 09140 Cellular Processes
  09143 Cell growth and death
   04110 Cell cycle
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04115 p53 signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04218 Cellular senescence
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
 09150 Organismal Systems
  09152 Endocrine system
   04921 Oxytocin signaling pathway
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   04928 Parathyroid hormone synthesis, secretion and action
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05202 Transcriptional misregulation in cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05206 MicroRNAs in cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05205 Proteoglycans in cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05203 Viral carcinogenesis
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
  09162 Cancer: specific types
   05210 Colorectal cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05212 Pancreatic cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05225 Hepatocellular carcinoma
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05226 Gastric cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05214 Glioma
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05216 Thyroid cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05220 Chronic myeloid leukemia
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05217 Basal cell carcinoma
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05218 Melanoma
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05211 Renal cell carcinoma
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05219 Bladder cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05215 Prostate cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05213 Endometrial cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05224 Breast cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05222 Small cell lung cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05223 Non-small cell lung cancer
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
  09172 Infectious disease: viral
   05166 Human T-cell leukemia virus 1 infection
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05161 Hepatitis B
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05160 Hepatitis C
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05163 Human cytomegalovirus infection
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05167 Kaposi sarcoma-associated herpesvirus infection
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05169 Epstein-Barr virus infection
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   05165 Human papillomavirus infection
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
  09167 Endocrine and metabolic disease
   04934 Cushing syndrome
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
  09176 Drug resistance: antineoplastic
   01524 Platinum drug resistance
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
   01522 Endocrine resistance
    K06625  CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
Other DBs
GO: 0004861
Genes
HSA: 1026(CDKN1A)
PTR: 104001067(CDKN1A)
PPS: 100977916(CDKN1A)
GGO: 101126640(CDKN1A)
PON: 100453682(CDKN1A)
NLE: 100599083(CDKN1A)
MCC: 719199(CDKN1A)
MCF: 102136063(CDKN1A)
CSAB: 103221583(CDKN1A)
CATY: 105592567(CDKN1A)
PANU: 100999911(CDKN1A)
RRO: 104682880(CDKN1A)
RBB: 108528336(CDKN1A)
TFN: 117087134(CDKN1A)
CJC: 100894215(CDKN1A)
SBQ: 101041919(CDKN1A)
MMUR: 105861439(CDKN1A)
MMU: 12575(Cdkn1a)
MCAL: 110283679(Cdkn1a)
MPAH: 110338236(Cdkn1a)
RNO: 114851(Cdkn1a)
MCOC: 116075178(Cdkn1a)
MUN: 110546586(Cdkn1a)
CGE: 103160601(Cdkn1a)
PLEU: 114706157(Cdkn1a)
NGI: 103739652(Cdkn1a)
HGL: 101710552(Cdkn1a)
CCAN: 109696503(Cdkn1a)
OCU: 100348489(CDKN1A)
TUP: 102490159(CDKN1A)
CFA: 474890(CDKN1A)
VVP: 112913942(CDKN1A)
VLG: 121473591(CDKN1A)
AML: 100484923(CDKN1A)
UMR: 103665536(CDKN1A)
UAH: 113243864(CDKN1A)
ORO: 101375107(CDKN1A)
ELK: 111147618
MPUF: 101671066(CDKN1A)
EJU: 114222230(CDKN1A)
MLX: 118000822(CDKN1A)
FCA: 493943(CDKN1A)
PTG: 102964051(CDKN1A)
PPAD: 109271531(CDKN1A)
AJU: 106972797(CDKN1A)
HHV: 120233834(CDKN1A)
BTA: 513497(CDKN1A)
BOM: 102268672(CDKN1A)
BIU: 109577247(CDKN1A)
BBUB: 102403077(CDKN1A)
CHX: 102179898(CDKN1A)
OAS: 100302083(CDKN1A)
ODA: 120870199(CDKN1A)
SSC: 100152215(CDKN1A)
CFR: 102509404(CDKN1A)
CDK: 105101330(CDKN1A)
BACU: 103005082(CDKN1A)
LVE: 103080733(CDKN1A)
OOR: 101288384(CDKN1A)
DLE: 111178743(CDKN1A)
PCAD: 102995437(CDKN1A)
ECB: 100064022(CDKN1A)
EPZ: 103564535(CDKN1A)
EAI: 106824579(CDKN1A)
MYB: 102245891(CDKN1A)
MYD: 102773038(CDKN1A)
MMYO: 118659964(CDKN1A)
MNA: 107545578(CDKN1A)
HAI: 109395991(CDKN1A)
DRO: 112302262(CDKN1A)
SHON: 118998962(CDKN1A)
AJM: 119050063(CDKN1A)
MMF: 118621843(CDKN1A)
PALE: 102894049(CDKN1A)
RAY: 107514682(CDKN1A)
MJV: 108385913(CDKN1A)
LAV: 100671706(CDKN1A)
TMU: 101342008
MDO: 100029103(CDKN1A)
SHR: 100926666(CDKN1A)
PCW: 110217257(CDKN1A)
OAA: 114813305(CDKN1A)
GGA: 378914(CDKN1A)
PCOC: 116236924(CDKN1A)
MGP: 104914505(CDKN1A)
CJO: 107324690(CDKN1A)
NMEL: 110388091(CDKN1A)
APLA: 101796138(CDKN1A)
ACYG: 106031068 106048467(CDKN1A)
TGU: 105759380(CDKN1A)
LSR: 110473068(CDKN1A)
SCAN: 103822335(CDKN1A)
PMOA: 120497652(CDKN1A)
GFR: 102041135(CDKN1A)
FAB: 101811025(CDKN1A)
PHI: 102112135(CDKN1A)
PMAJ: 107214716(CDKN1A)
CCAE: 111944648(CDKN1A)
CCW: 104692419(CDKN1A)
ETL: 114064409(CDKN1A)
FCH: 114014226(CDKN1A)
CLV: 102096820(CDKN1A)
NNI: 104010373(CDKN1A) 104012649
ACUN: 113488931(CDKN1A) 113491306(CDKN1B)
PADL: 103917239 103925936(CDKN1A)
AAM: 106484396(CDKN1A) 106488969
ASN: 102368723(CDKN1B) 102379358(CDKN1A)
AMJ: 102567302(CDKN1D) 102568235(CDKN1A)
CPOO: 109317512(CDKN1A)
GGN: 109295209(CDKN1A)
PSS: 102450716(CDKN1A) 102453637
CMY: 102939737(CDKN1A) 102940507
CPIC: 101938764(CDKN1A) 101953786
TST: 117875921(CDKN1A) 117884239
CABI: 116838036 116839143(CDKN1A)
ACS: 100555337(cdkn1a)
PVT: 110075002 110079972(CDKN1A)
PBI: 103052025(CDKN1A) 103053360
PMUR: 107287054(CDKN1A)
TSR: 106541210(CDKN1A)
PGUT: 117663994(CDKN1A)
PMUA: 114599215(CDKN1A)
ZVI: 118088627(CDKN1A)
GJA: 107111179 107117358(CDKN1A)
XLA: 108709405(cdkn1a.S) 492305(cdkn1a.L)
XTR: 100038054(cdkn1a)
DRE: 100151416(cdkn1a)
IPU: 108281086(cdkn1a)
PHYP: 113539506
AMEX: 103041774 103047217(cdkn1a)
EEE: 113573558 113586971(cdkn1a)
TRU: 105417819
NCC: 104948695
ELY: 117249374(cdkn1d) 117256340(cdkn1a)
PLEP: 121951189(cdkn1a) 121961391(cdkn1d)
SLUC: 116039798(cdkn1d) 116041628(cdkn1a)
GAT: 120817084(cdkn1d) 120834939(cdkn1a)
MSAM: 119886232(cdkn1a) 119918434(cdkn1d)
CUD: 121505410(cdkn1d) 121529301(cdkn1a)
OAU: 116333861(cdkn1a)
OML: 112144588(cdkn1a) 112158072
PRET: 103465183
CVG: 107085617
NFU: 107385762
KMR: 108241005(cdkn1d) 112450491(cdkn1a)
AOCE: 111574372
CSEM: 103385882
POV: 109629024
XGL: 120800817(cdkn1d) 120806924(cdkn1a)
BPEC: 110168634
OMY: 110490248(cdkn1d) 110494354(cdkn1a) 110500225 110528083
LOC: 102697870(cdkn1a)
ARUT: 117395326 117964374(cdkn1a)
LCM: 102361382(CDKN1A)
CMK: 103179079(cdkn1a) 103179335
RTP: 109923052(cdkn1b)
AME: 725144
BIM: 100740661
BTER: 100643680
OBB: 114872802
CFO: 105258549
TCA: 107397827
DPA: 109533541
ATD: 109594574
BANY: 112051090
ZCE: 119837499
CSEC: 111870931
VDE: 111249633
VJA: 111272573
PTEP: 107443706
PCAN: 112566296
LAK: 106178439
PDAM: 113675332
 » show all
Reference
  Authors
Abbas T, Dutta A
  Title
p21 in cancer: intricate networks and multiple activities.
  Journal
Nat Rev Cancer 9:400-14 (2009)
DOI:10.1038/nrc2657
Reference
PMID:8242751
  Authors
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ
  Title
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
  Journal
Cell 75:805-16 (1993)
DOI:10.1016/0092-8674(93)90499-G
  Sequence
[hsa:1026]
LinkDB

DBGET integrated database retrieval system